MONTREAL, CANADA--(Marketwire - April 17, 2008) - ProMetic Life Sciences Inc. (TSX: PLI) ("ProMetic") announced results of three compounds in preclinical studies for prostate and pancreatic cancer at the American Association for Cancer Research ("AACR") Annual Meeting 2008 being held in San Diego this week.
